Press Release February 9, 2022BIIB Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Biogen, Inc. Investors of Class Action and Encourages Investors to Contact the Firm 0 0 Share
Press Release February 9, 2022Shareholder Alert: Robbins LLP Informs Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders 0 0 Share
Press Release February 8, 2022BIOGEN INC. (NASDAQ: BIIB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc. (NASDAQ: BIIB) 0 0 Share
Company Ticker News February 8, 2022Biogen (BIIB) Inks Agreement to Add New Biosimilar Candidate 0 0 Share
Company Ticker News February 8, 2022Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane 0 0 Share
Press Release February 7, 2022Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA® (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis 0 0 Share
Company Ticker News February 4, 2022Biogen's Aduhelm Approval, Marketing Comes Under FTC, SEC Probes 0 0 Share
Company Ticker News February 4, 2022Biogen facing civil demand from FTC, inquiry from SEC about Alzheimer's drug 0 0 Share
Company Ticker News February 3, 2022Biogen Inc. (BIIB) CEO Michel Vounatsos on Q4 2021 Results - Earnings Call Transcript 0 0 Share
